- 5-Amino-1MQ (5A1MQ)
Small-molecule NNMT inhibitor that reduced body weight and white fat mass in diet-induced obese mice. Proposed to act by raising intracellular NAD+ and SAM…
- Adipotide (FTPP) (FTPP)
Adipotide (also known as FTPP or prohibitin-targeting peptide) is a peptidomimetic that targets blood vessels supplying white adipose tissue, causing fat cell…
- AOD-9604 (AOD)
Fragment of human growth hormone (amino acids 176-191) studied for obesity in early-phase human trials; weight-loss efficacy was not established in published…
- Dulaglutide (DULA)
Dulaglutide (marketed as Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes. It consists of a GLP-1 analog fused to a…
- Exenatide (EXEN)
Exenatide (marketed as Byetta and Bydureon) is a GLP-1 receptor agonist originally derived from the saliva of the Gila monster lizard. It was the first…
- Liraglutide (LIRA)
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It shares 97% homology with…
- MOTS-c (MOTSC)
Mitochondria-derived peptide that regulates metabolic homeostasis; in mice it prevented diet-induced obesity and insulin resistance.
- Retatrutide (RETA)
Triple agonist targeting GIP, GLP-1, and glucagon receptors. In a phase 2 trial of 338 adults with obesity, the 12 mg dose produced a least-squares mean weight…
- Semaglutide (SEMA)
GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy. Semaglutide is a…
- Tirzepatide (TIRZ)
Dual GIP/GLP-1 receptor agonist. In the SURMOUNT-1 Phase 3 trial, mean weight reduction was 15-21% at 72 weeks vs 3.1% with placebo. Brand names include…